COLCHICINE IN THE PREVENTION OF ARDS IN HOSPITALIZED COVID-19 PATIENTS: A RETROSPECTIVE ANALYSIS
Critical Care Medicine
; 50:96-96, 2022.
Article
in English
| Academic Search Complete | ID: covidwho-1596378
ABSTRACT
Many COVID19 patients develop Acute Respiratory Distress Syndrome (ARDS), resulting from an uncontrolled inflammatory response to infection. B Results:
b Of the 54 patients treated with colchicine, 8 developed ARDS, while 2 developed ARDS in the control group (14.81% vs 3.70%;I P i =0.05;odds ratio [OR] 4.52 [95% confidence interval {CI} 0.91-22.38]). [Extracted from the article] Copyright of Critical Care Medicine is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
Full text:
Available
Collection:
Databases of international organizations
Database:
Academic Search Complete
Type of study:
Observational study
Language:
English
Journal:
Critical Care Medicine
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS